Clinical Scorecard: This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet
At a Glance
| Category | Detail |
|---|---|
| Condition | Multiple myeloma, inherited hearing loss, stiff person syndrome, drug-resistant epilepsy, aggressive thyroid cancers |
| Key Mechanisms | In vivo CAR-T cell generation via lentiviral delivery, gene therapy via AAV vectors, CD19-targeting CAR-T, neuronal cell therapy delivering inhibitory neurons, ICAM-1 targeting CAR-T |
| Target Population | Patients with multiple myeloma, OTOF-related sensorineural hearing loss, stiff person syndrome, drug-resistant mesial temporal lobe epilepsy, advanced thyroid cancers |
| Care Setting | Specialized oncology, neurology, and gene therapy centers with capabilities for advanced cellular and gene therapies |
Key Highlights
- Lilly’s $7B acquisition of Kelonia aims to advance in vivo CAR-T therapies simplifying manufacturing by generating CAR-T cells directly in patients.
- FDA approved Regeneron’s Otarmeni, the first gene therapy for OTOF-related hearing loss, showing significant hearing improvement in clinical trials.
- CAR-T therapies demonstrate durable clinical benefits in stiff person syndrome, early multiple myeloma, and aggressive thyroid cancers with manageable safety profiles.
Guideline-Based Recommendations
Diagnosis
- Identify genetic causes such as OTOF mutations for sensorineural hearing loss to consider gene therapy eligibility.
- Diagnose multiple myeloma and assess risk stage to evaluate suitability for early CAR-T intervention.
- Confirm diagnosis of stiff person syndrome and refractory status to prior immunomodulatory therapies before CAR-T consideration.
- Evaluate drug-resistant mesial temporal lobe epilepsy patients for potential regenerative neuronal cell therapy.
Management
- Consider in vivo CAR-T therapies like KLN-1010 for multiple myeloma to reduce manufacturing complexity and treatment timelines.
- Administer Otarmeni gene therapy via intracochlear infusion as a one-time treatment for eligible OTOF-related hearing loss patients.
- Use CD19-targeting CAR-T (mivocabtagene autoleucel) as a single infusion in stiff person syndrome patients unresponsive to prior treatments.
- Apply neuronal cell therapy (NRTX-1001) for drug-resistant epilepsy to restore inhibitory neural circuits.
- Employ ICAM-1 targeting CAR-T (AIC100) in advanced thyroid cancers with dose adjustments based on tolerability.
Monitoring & Follow-up
- Monitor for cytokine release syndrome and neurotoxicity during and after CAR-T therapies, noting low-grade events in early trials.
- Assess hearing improvement and auditory function post-Otarmeni administration.
- Evaluate mobility, stiffness, and disability metrics longitudinally in stiff person syndrome patients receiving CAR-T.
- Track seizure frequency and neurological function in epilepsy patients treated with neuronal cell therapy.
- Perform imaging and clinical assessments to monitor response and adverse events in thyroid cancer CAR-T therapy.
Risks
- Potential cytokine release syndrome and pneumonitis associated with CAR-T therapies, though high-grade events were rare or absent in reported trials.
- Risks related to intracochlear infusion procedures for gene therapy administration.
- Uncertainties regarding long-term durability and safety of novel in vivo CAR-T and regenerative therapies.
Patient & Prescribing Data
Patients with high-risk smoldering multiple myeloma, OTOF-related hearing loss, stiff person syndrome refractory to immunotherapies, drug-resistant epilepsy, and advanced thyroid cancers
One-time intravenous or intracochlear administration of gene or CAR-T therapies shows promising durable efficacy and manageable safety profiles, supporting earlier intervention and potential for long-term disease control.
Clinical Best Practices
- Select patients based on genetic and clinical criteria to optimize eligibility for gene and CAR-T therapies.
- Implement rigorous monitoring protocols for early detection and management of immune-related adverse events.
- Leverage emerging in vivo CAR-T platforms to simplify treatment delivery and improve patient access.
- Incorporate multidisciplinary care teams including oncology, neurology, and gene therapy specialists for comprehensive management.
- Educate patients on potential benefits and risks of novel cellular and gene therapies to support informed decision-making.
References
- Lilly to acquire Kelonia Therapeutics for in vivo CAR-T platform
- FDA approves Otarmeni for OTOF-related hearing loss
- Kyverna Therapeutics reports Phase 2 results in stiff person syndrome
- UCB acquires Neurona Therapeutics for epilepsy regenerative therapy
- Dana-Farber reports CAR-T efficacy in early multiple myeloma
- MD Anderson reports Phase I CAR-T trial in thyroid cancers
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
